斑塊性乾癬、乾癬性關節炎 Plaque psoriasis; Psoriatic arthritis

Anti-interleukin 17A Monoclonal Antibody
Ixekizumab selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines.

Abxorption: Bioavailability 60% to 81%
Distribution: Vdss: 7.1 L
Metabolism: Expected to be degraded into small peptides and amino acids via catabolic pathways similar to that which is seen with endogenous IgG
Pharmacodynamics:
1. Half-life elimination: 13 days
2. Time to peak: ~4 days

Serious hypersensitivity reaction (eg, anaphylaxis) to ixekizumab or any component of the formulation

Adverse events were not observed in animal reproduction study, however an increase in neonatal deaths was observed when dosing continued throughout pregnancy. Human IgG is known to cross the placenta.
Other agents are currently preferred for the treatment of plaque psoriasis in pregnant women.

It is not known if ixekizumab is excreted in breast milk.
According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.

Neutropenia, Antibody development, Infection, Injection site reaction (erythema and pain), Upper respiratory tract infection

Plaque psoriasis: (SubQ) 160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10 and 12, and then 80 mg every 4 weeks.
Psoriatic arthritis: (SubQ) 160 mg once, followed by 80 mg every 4 weeks; may administer alone or in combination with conventional disease-modifying antirheumatic drugs (eg, methotrexate).
Note: For psoriatic arthritis patients with coexisting moderate-to-severe plaque psoriasis, use the dosing regimen for plaque psoriasis.

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).